Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.84 and traded as high as $2.90. Vistagen Therapeutics shares last traded at $2.87, with a volume of 182,113 shares changing hands.
Vistagen Therapeutics Price Performance
The company's 50 day simple moving average is $2.85 and its 200 day simple moving average is $2.97. The stock has a market cap of $76.20 million, a P/E ratio of -1.78 and a beta of 0.77.
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.02. The company had revenue of $230 billion during the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. On average, equities research analysts predict that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current year.
Hedge Funds Weigh In On Vistagen Therapeutics
Several institutional investors have recently modified their holdings of the business. Two Sigma Advisers LP bought a new stake in Vistagen Therapeutics during the 4th quarter worth approximately $35,000. Two Sigma Investments LP increased its position in shares of Vistagen Therapeutics by 123.2% during the fourth quarter. Two Sigma Investments LP now owns 137,334 shares of the company's stock worth $405,000 after acquiring an additional 75,792 shares in the last quarter. Stempoint Capital LP raised its holdings in shares of Vistagen Therapeutics by 26.1% during the fourth quarter. Stempoint Capital LP now owns 2,328,492 shares of the company's stock worth $6,869,000 after acquiring an additional 481,700 shares during the period. Man Group plc bought a new stake in Vistagen Therapeutics in the 4th quarter valued at $54,000. Finally, Millennium Management LLC boosted its stake in Vistagen Therapeutics by 52.9% in the 4th quarter. Millennium Management LLC now owns 38,732 shares of the company's stock worth $114,000 after purchasing an additional 13,395 shares during the period. Institutional investors own 78.39% of the company's stock.
About Vistagen Therapeutics
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Featured Articles
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
